Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Jennifer Caswell-Jin, MD is an Assistant Professor of Medicine (Oncology) specializing in breast cancer care and research. She received her medical degree from Harvard Medical School in 2010, completed her internal medicine residency at the University of California, San Francisco in 2013, and completed her clinical fellowship in medical oncology at Stanford Hospital & Clinics in 2017. Her clinical translational research program is aimed at developing personalized approaches to care that improve the outcomes of people with breast cancer.
View Full Biography
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2013) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2018)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2013)
- Medical Education: Harvard Medical School (2010) MA
- A.B., Harvard College, Biological Anthropology (2006)
Honors & Awards
- AACR Associate Member Award, San Antonio Breast Cancer Symposium (2018)
- ASCO Young Investigator Award, Conquer Cancer Foundation (2017)
- Physician Scientist Training Award, Damon Runyon Cancer Research Foundation (2017)
- Postdoctoral Fellowship Award, Susan G. Komen (2017)
- SCI Fellowship Award, Stanford Cancer Institute (2017)
Publications
-
Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25
Fejerman, L., Ahmadiyeh, N., Hu, D., Huntsman, S., Beckman, K. B., Caswell, J. L., … Ziv, E. (2014). Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. NATURE COMMUNICATIONS, 5. -
Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors
Caswell, J. L., Camarda, R., Zhou, A. Y., Huntsman, S., Hu, D., Brenner, S. E., … Ziv, E. (2015). Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. HUMAN MOLECULAR GENETICS, 24(25), 7421–31. -
High mammographic density in women of Ashkenazi Jewish descent
Caswell, J. L., Kerlikowske, K., Shepherd, J. A., Cummings, S. R., Hu, D., Huntsman, S., & Ziv, E. (2013). High mammographic density in women of Ashkenazi Jewish descent. BREAST CANCER RESEARCH, 15(3). -
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
Ziv, E., Dean, E., Hu, D., Martino, A., Serie, D., Curtin, K., … Vachon, C. (2015). Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. NATURE COMMUNICATIONS, 6. -
Analysis of chimpanzee history based on genome sequence alignments
Caswell, J. L., Mallick, S., Richter, D. J., Neubauer, J., Gnerre, C. S. S., Gnerre, S., & Reich, D. (2008). Analysis of chimpanzee history based on genome sequence alignments. PLOS GENETICS, 4(4). -
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
Ahmadiyeh, N., Pomerantz, M. M., Grisanzio, C., Herman, P., Jia, L., Almendro, V., … Freedman, M. L. (2010). 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(21), 9742–9746. -
Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–64. -
Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2017). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing? JCO Precision Oncology. -
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin, J. L., McNamara, K., Reiter, J. G., Sun, R., Hu, Z., Ma, Z., … Curtis, C. (2019). Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications, 10(1), 657. -
Response to Peshkin, Isaacs, and Schwartz.
Caswell-Jin, J. L., & Kurian, A. W. (2019). Response to Peshkin, Isaacs, and Schwartz. Journal of the National Cancer Institute. -
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Rueda, O. M., Sammut, S.-J., Seoane, J. A., Chin, S.-F., Caswell-Jin, J. L., Callari, M., … Curtis, C. (2019). Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. -
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., … Kurian, A. W. (2018). Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2(4), pky062. -
Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., & Tamang, S. R. (2019). Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. . JAMIA Open. -
Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative
Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., & Kurian, A. W. (2019). Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(1), 95–98. -
Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.
Banerjee, I., Bozkurt, S., Caswell-Jin, J. L., Kurian, A. W., & Rubin, D. L. (2019). Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. JCO Clinical Cancer Informatics, 3, 1–12. -
Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Seoane, J. A., Kirkland, J. G., Caswell-Jin, J. L., Crabtree, G. R., & Curtis, C. (2019). Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nature Medicine. -
Re: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative Response
Caswell-Jin, J. L., & Kurian, A. W. (2019). Re: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative Response. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(8), 874. -
Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., & Tamang, S. R. (2019). Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. JAMIA Open, 2(4), 528–37. -
Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
Kurian, A. W., Bernhisel, R., Larson, K., Caswell-Jin, J. L., Shadyab, A. H., Ochs-Balcom, H., & Stefanick, M. L. (2020). Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. JAMA, 323(10), 995–97. -
Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial
Caswell-Jin, J. L., McNamara, K. L., Dering, J., Chen, H.-W., Dichmann, R., Perez, A., … Hurvitz, S. A. (2020). Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial. CANCER RESEARCH, 80(4). -
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Hurvitz, S. A., Caswell-Jin, J. L., McNamara, K. L., Zoeller, J. J., Bean, G. R., Dichmann, R., … Slamon, D. J. (2020). Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 11(1), 5824. -
Androgen receptor agonists as breast cancer therapeutics.
Caswell-Jin, J. L., & Curtis, C. (2021). Androgen receptor agonists as breast cancer therapeutics. Nature Medicine. -
Molecular Heterogeneity and Evolution in Breast Cancer
Caswell-Jin, J. L., Lorenz, C., & Curtis, C. (2021). Molecular Heterogeneity and Evolution in Breast Cancer. Annual Review of Cancer Biology, 5. -
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., … Curtis, C. (2021). Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. NATURE CANCER, 2(4), 400-+. -
Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.
Caswell-Jin, J. L., Callahan, A., Purington, N., Han, S. S., Itakura, H., John, E. M., … Kurian, A. W. (2021). Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics, 5, 600–614. -
Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
Kurian, A. W., Hughes, E., Simmons, T., Bernhisel, R., Probst, B., Meek, S., … Stefanick, M. L. (2021). Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. Cancer. -
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi, A., Marsh, S., Winchester, A., Gao, D., Parris, H., Axell, L., … Tung, N. M. (2021). Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? JCO Precision Oncology, 2, 1–10. -
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Parikh, D. A., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., … Caswell-Jin, J. L. (2022). Patient perspectives on window of opportunity clinical trials in early-stage breast cancer. Breast Cancer Research and Treatment. -
Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
Bean, G. R., Najjar, S., Shin, S. J., Hosfield, E. M., Caswell-Jin, J. L., Urisman, A., … Krings, G. (2022). Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. -
Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.
Caswell-Jin, J. L., Shafaee, M. N., Xiao, L., Liu, M., John, E. M., Bondy, M. L., & Kurian, A. W. (2022). Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population. Breast Cancer Research and Treatment. -
Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.
Kurian, A. W., Abrahamse, P., Hamilton, A. S., Caswell-Jin, J. L., Gomez, S. L., Hofer, T. J., … Katz, S. J. (2022). Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment. JNCI Cancer Spectrum. -
Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017.
Caswell-Jin, J. L., Sun, L., Munoz, D., Lu, Y., Li, Y., Huang, H., … Plevritis, S. (2022). Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.
Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J. L., … Rosen, E. (2022). First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., & Neal, J. W. (2023). Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC. CardioOncology, 5(1), 85–98. -
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer.
Rosen, E., Sharma, M., Berz, D., Caswell-Jin, J. L., Spira, A. I., Fulgar, G. A., … Meric-Bernstam, F. (2023). Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Analysis of Breast Cancer Mortality in the US-1975 to 2019.
Caswell-Jin, J. L., Sun, L. P., Munoz, D., Lu, Y., Li, Y., Huang, H., … Plevritis, S. K. (2024). Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA, 331(3), 233–241. -
US Breast Cancer Mortality-Reply.
Caswell-Jin, J. L., Kurian, A. W., & Plevritis, S. K. (2024). US Breast Cancer Mortality-Reply. JAMA. -
Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
Trentham-Dietz, A., Chapman, C. H., Jayasekera, J., Lowry, K. P., Heckman-Stoddard, B. M., Hampton, J. M., … Mandelblatt, J. S. (2024). Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force. JAMA. -
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
Freedman, R. A., Caswell-Jin, J. L., Hassett, M., Somerfield, M. R., & Giordano, S. H. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400886. -
The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study.
Wojcik, K. M., Caswell-Jin, J. L., Wilson, O. W., Schechter, C., Kamil, D., Kurian, A. W., & Jayasekera, J. (2024). The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study. BMC Cancer, 24(1), 975. -
Use of surgery for de novo metastatic breast cancer (mBC)
Dickerson, J., Tang, H., Thompson, C., Gomez, S. L., Satoyoshi, M., Kurian, A. W., & Caswell-Jin, J. L. (2024). Use of surgery for de novo metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.
Caswell-Jin, J. L., Freedman, R. A., Hassett, M. J., Tang, H., Garrett-Mayer, E., Somerfield, M. R., & Giordano, S. H. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights. JCO Oncology Practice, OP2400663.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CA
Stanford Women's Cancer Center
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereBreast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Breast Cancer Program in Palo Alto
900 Blake Wilbur Drive, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(44 reviews)
I appreciated the level of her, and her PA’s, communication. It was clear without being either oversimplified nor erudite.
The first person I talked to was Nellian Manis, genetic counselor ,She was a very pleasant lady, We go over my medical, family history and result of my past genetic tests as well as the current thing going in the field of genetic testing .She explained things well and thoroughly , answer my questions . Then we connected to Dr Caswell-Jin who was equally nice and pleasant ,discussed and answer my questions well. Very happy with Dr Caswell-Jin and Nellian Manis.,Excellent providers .Thank you .
Relates extremely well
What an excellent physician!
I feel very comfortable transferring my care to her.
Very professional and easy to understand and talk to.
I appreciated her answers to mine and my daughter's questions. Clearly, she is very informed in her subject matter.
I love that Dr Caswell always listens patiently, be responsive to hundreds of questions I bring up (both live and via app), and provides detailed post-visit notes. I always feel like Dr Caswell prioritizes my need and I’m in good hands and great partnership. Thanks so much for your care and expertise!
Very helpful :)
She was very understanding,explained all details put my mind at ease.I have been feeling so depressed wondering about me getting cancer throughout many year's I really enjoyed our video call I felt like she's i really trying to get me help on getting my testing done.
Thank you
She is well organized, very knowledgeable, highly professional, and was an absolute delight to talk with throughout the entire conference. She has a wonderful ability to listen, as well as to make patients feel comfortable.. all questions were answered clearly, often with specific exa.ples.
Addressed my questions and concerns thoroughly
She was very nice, and I felt comfortable talking with her about my medical condition.
I was extremely happy with the information Dr. Caswell gave me.
Very thoughtful and caring provider.
She was very experienced and demonstrated a deep knowledge about a complex subject. In addition, she was able to explain it to me in terms I could understand.
Jennifer is excellent in every way
She is very knowledgeable in the field of cancer genetics and answered all my questions. She gave me very good advice to live my life from now on.
Jennifer Caswell was professional, knowledgeable, and open to any and all questions.
She listens well
She really wants to help me and is genuinely interested in making me feel better with the side effects of the medication
I also want to acknowledge Aileen
She is very kind and thoughtful and stayed late on a Friday night just so I could have a good weekend
And also dr bergstrom is very good
And gives me so much encouragement
Thank you
Very kind doctor
i have and will continue to do so.
She is super friendly, gives detailed explanations. She’s great!
The best
I would and have recommended Dr. Caswell to other cancer patients . She and her staff are always kind ,considerate and knowledgeable !
Careful, thoughtful, caring.
I'm very happy to have Dr. Jennifer Caswell-Jin as my doctor, she is very thorough, kind and compassionate.
Dr.Caswell is wonderful!
Awesome doctor goes over everything with me and explains clearly.
I am in good hands and very lucky !!
Dr Caswell consistently provide great service and she genuinely cares about me.
I think Dr. Casewell is a honest , compassionate, and great doctor.
Dr. Caswell Jin has an extensive knowledge of oncology and is very compassionate. Amazing
Very good doctor !!!
Dr. Caswell-Jin is an excellent communicator and physician. I feel lucky to have her as my doctor.
She’s very quick and efficient and seemed to address all the issues regarding my health
Very professional and got right to the point. I felt very comfortable it was easy talking to her.
I really like her medical care and information she gave me regarding my metastasis breast cancer and the next steps I need to take for treatments
Excellant
Best doctor ever
She is so kind and helpful. We always feel so much better after we’ve talked to her.
She's very attentive and helpful. Shows a lot of compassion.
She is very understanding, encouraging and compassionate. I like her as a secondary doctor regarding my health concerns. She listens and makes me feel comfortable.
Dr. Caswell-Jin is terrific. She explains clearly and explores various possible treatment options. I have confidence in her knowledge and caring and rely on her expertise.
She’s so informative and I always feel so much better after our calls.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records